
FDA Approves Pertuzumab Biosimilar in HER2-Positive Breast Cancer
Key Takeaways
- FDA labeling includes first-line HER2-positive metastatic disease with trastuzumab/docetaxel and early-stage neoadjuvant or adjuvant therapy with trastuzumab plus chemotherapy in higher-risk populations.
- Regulatory support emphasized biosimilarity via extensive analytical characterization and comparative pharmacokinetics, with no clinically meaningful differences across safety, efficacy, quality, or immunogenicity.
The approval of pertuzumab-qcay (Pebrilzo) covers metastatic and early-stage HER2-positive breast cancer, but a patent settlement with Genentech delays its earliest US launch until the third quarter of 2028.
The FDA has approved pertuzumab-qcay (Pebrilzo), a biosimilar to pertuzumab (Perjeta), for the treatment of adults with HER2-positive breast cancer across metastatic and early-stage disease settings, according to a November 16, 2026, announcement from Biocon Limited. Although the approval expands the number of FDA-approved pertuzumab products, US commercial availability is not expected until the third quarter of 2028 under a previously announced settlement and license agreement with Genentech.¹˒²
The approval adds to the treatment landscape for HER2-positive breast cancer, a subtype characterized by overexpression of HER2 or amplification of the HER2 gene. Approximately 15% to 20% of breast cancers are HER2-positive.³ The American Cancer Society estimates that 321,910 patients in the United States will be diagnosed with invasive breast cancer in 2026.⁴
Pebrilzo Is Approved Across Metastatic and Early-Stage Disease
Pertuzumab is a monoclonal antibody that targets HER2 receptors on cancer cells. By binding to HER2 and preventing receptor pairing with other HER family members, the treatment interferes with signaling pathways involved in tumor cell growth and survival.
Under the FDA approval, pertuzumab-qcay is indicated in combination with trastuzumab (Herceptin) and docetaxel for adults with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.¹
The biosimilar is also approved for use with trastuzumab and chemotherapy in 2 early breast cancer settings. These include neoadjuvant treatment for adults with HER2-positive locally advanced, inflammatory, or early-stage disease (tumors greater than 2 cm or node-positive disease) as part of a complete treatment regimen. The other indication covers adjuvant treatment for adults with HER2-positive early breast cancer at high risk of recurrence.
FDA Approval Was Supported by Analytical and Pharmacokinetic Data
According to Biocon, the approval of pertuzumab-qcay was supported by a comprehensive data package that included structural and functional characterization, analytical similarity assessments, and comparative clinical pharmacokinetic data. The company reported that these data demonstrated high similarity to the reference product, with no clinically meaningful differences in quality, safety, efficacy, or immunogenicity.
Other
Pertuzumab-qcay is not the first FDA-approved biosimilar to Perjeta. On November 13, 2025, the
US Launch Is Not Expected Until 2028
Although FDA approval has been secured, Biocon’s ability to commercialize pertuzumab-qcay in the United States is subject to the terms of its global settlement and license agreement with Genentech. Announced October 14, 2026, the agreement resolved pending disputes between the companies, including those in the United States, Canada, and other jurisdictions.²
Under the agreement, Biocon identified the third quarter of calendar year 2028 as the earliest licensed US launch date for Pebrilzo. The company also identified the first quarter of 2027 as the earliest licensed launch period in the European Union and United Kingdom, subject to regulatory approval.2
The European Medicines Agency’s Committee for Medicinal Products for Human Use issued a positive opinion in September 2026 recommending marketing authorization for Biocon’s pertuzumab biosimilar, formulated as a 420-mg/14-mL concentrate for infusion, for HER2-positive breast cancer across multiple disease stages.¹
Pebrilzo Expands Biocon’s Oncology Portfolio
The company is also developing proposed biosimilars to trastuzumab/hyaluronidase, nivolumab (Opdivo), and pembrolizumab (Keytruda), extending its pipeline across HER2-directed treatment and immuno-oncology.
“The U.S. FDA approval of Pebrilzo, our biosimilar pertuzumab, marks another significant milestone in Biocon’s journey to expand access to high-quality biosimilars,” Shreehas Tambe, CEO and managing director of Biocon Limited, said in the company’s news release.
REFERENCES
1. Biocon gets U.S. FDA approval for Pebrilzo (pertuzumab-qcay) injection, a biosimilar to Perjeta, expanding its oncology portfolio. News release. Biocon Limited. November 16, 2026. Accessed November 16, 2026. https://tinyurl.com/3uh3yfhe
2. Biocon secures earliest licensed launch dates for Pebrilzo (bPertuzumab) following global patent settlement with Genentech. News release. Biocon Limited. October 14, 2026. Accessed November 16, 2026. https://tinyurl.com/bdftpwx2
3. Breast cancer HER2 status. American Cancer Society. Accessed November 16, 2026. https://tinyurl.com/mr2a8kdw
4. Key statistics for breast cancer. American Cancer Society. Accessed November 16, 2026. https://tinyurl.com/bp94895y
5. FDA approves new interchangeable biosimilar to Perjeta. US FDA. November 13, 2025. Accessed November 16, 2026.https://tinyurl.com/4rvsyysh
Related to this article








